AI-powered embryonic phenotyping for accelerated drug discovery and toxicology

Descripción del proyecto

Aprendizaje profundo avanzado para acelerar el descubrimiento de fármacos y la toxicología

Los métodos tradicionales de ensayo de fármacos se basan en modelos animales, que requieren mucho tiempo, son costosos y plantean problemas éticos. El equipo del proyecto EmbryoNet-AI, financiado por el Consejo Europeo de Investigación, tiene como objetivo mejorar el descubrimiento de fármacos y las pruebas toxicológicas automatizando el análisis fenotípico de embriones y organoides mediante aprendizaje profundo avanzado. Esta plataforma permitirá realizar evaluaciones más rápidas y precisas de los efectos de los compuestos, lo que reducirá la dependencia de los modelos animales. Centrado en el desarrollo y la comercialización, el proyecto perfeccionará los modelos de inteligencia artificial (IA o IA,por sus siglas en inglés), creará una interfaz web fácil de usar y colaborará con socios. Al mejorar los métodos de ensayo tradicionales, en EmbryoNet-AI se pretende acelerar el descubrimiento de fármacos, abaratar costes y apoyar la investigación sostenible en biología del desarrollo y farmacología.

Objetivo

The EmbryoNet-AI project seeks to transform drug discovery and toxicology testing by integrating advanced deep learning technologies to automate phenotypic analysis of embryos and organoids. Traditional drug testing methods rely heavily on animal models, which are time-consuming, costly, and often ethically problematic. EmbryoNet-AI offers a faster, more accurate, and comprehensive solution for evaluating the effects of compounds on biological development, thus significantly enhancing the efficiency of early-stage drug screening. The core innovation is EmbryoNet-AI's ability to analyze complex biological data with precision, providing insights into drug mechanisms that are not only quicker but also more reliable than current methods. This will ultimately reduce the need for animal models in drug testing, addressing both ethical and logistical concerns. The EmbryoNet-AI platform is poised to fill a critical gap in the pharmaceutical and biotech industries, offering a scalable, non-invasive approach that can be easily integrated into existing workflows. With the support of the ERC Proof of Concept grant, we will focus on the further development, validation, and commercialization of the EmbryoNet-AI platform. The project will involve refining our AI models through rigorous testing, building a prototype web interface for user interaction, and collaborating with industrial and academic partners to ensure the platforms practical utility. Additionally, we will explore intellectual property strategies and assess market readiness, paving the way for wide-spread adoption. By addressing the limitations of traditional phenotyping methods, EmbryoNet-AI aims to accelerate drug discovery, reduce costs, and promote more sustainable research practices in developmental biology and pharmacology. Through ERC funding, we aim to establish EmbryoNet-AI as a ground-breaking tool that will impact both the scientific community and the pharmaceutical industry.